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embryonic stem cells and the 
development of cancer
Gregor Prindull*
Medical Faculty, University of Göttingen, Göttingen, Germany
Objectives: This review is to explore whether potential gene interactions in the cell 
cycles of gametes, zygotes, and embryonic stem (ES) cells are associated with the 
development of cancer.
Methods: MEDPILOT at the Central Library of the University of Cologne, Germany 
(Zentralbibliothek Köln) that covers 5,800 international medical journals and 4,300 
E-journals was used to collect data. The initial searches were done in December 2012 
and additional searches in October 2013–May 2015. The search terms included “cancer 
development,” “gene interaction,” and “ES cells,” and the time period was between 1998 
and 2015. A total of 147 articles in English language only were included in this review.
Results: Transgenerational gene translation is implemented in the zygote through 
interactions of epigenetic isoforms of transcription factors (TFs) from parental gametes, 
predominantly during the first two zygote cleavages. Pluripotent transcription factors 
may provide interacting links with mutated genes during zygote-to-ES cell switches. 
Translation of post-transcriptional carcinogenic genes is implemented by abnormally 
spliced, tumor-specific isoforms of gene-encoded mRNA/non-coding RNA variants of 
TFs employing de novo gene synthesis and neofunctionalization. Post-translationally, 
mutated genes are preserved in pre-neoplastic ES cell subpopulations that can give 
rise to overt cancer stem cells. Thus, TFs operate as cell/disease-specific epigenetic 
messengers triggering clinical expression of neoplasms.
Conclusion: Potential gene interactions in the cell cycle of gametes, zygotes, and ES 
cells may play some roles in the development of cancer.
Keywords: gene transcription factors, gametes, zygotes, embryonic stem cells, pre-neoplastic
introduction
DNA-encoded gene replication is usually stable but not permanent during meiotic and mitotic cell 
cycles. Indeed, the genome can be interpreted as an evolutionary organ of epigenetic gene transcrip-
tion/translation; its complex gene replication patterns affect normal, as well as neoplastic cells (1, 2). 
The circumstances that lead to gene plasticity of normal cells, and neoplastic translational expression 
Full list of abbreviations is available as an Appendix at the end of this article.
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of mutated genes still are in part enigmatic. They may be initi-
ated during development of embryonic stem (ES) cells that are in 
bi-directional dynamic equilibria with their primordial germline 
stem cells (PGCs). ES cells receive both normal and neoplastic 
transgenerational information from their parents via gametes 
that interact with each other in the zygote. Genes of gametes, 
zygotes, ES cells, and cancer stem cells (CSCs) interact through 
chromatin histone-mediated transcription factors (TFs) with 
or without involving environmental risk factors, such as biotic 
stress. Pluripotent TFs (ppTFs) are essential for unlimited prolif-
eration and self-replication as epigenetic modulators in normal 
embryonic and neoplastic stem cells.
Mutagenic and carcinogenic properties of somatic cells are 
acquired by gene neosynthesis and neofunctionalization through 
alternative splicing of enzymatic messenger-/non-coding RNAs 
(m-/ncRNA) to isoforms that produce neoplastic effector 
proteins for translation (3, 4). It is not clear whether reactiva-
tion of silenced ES cells is involved in these processes (5, 6). 
Because ppTFs-mediated epithelial–mesenchymal/mesenchymal– 
epithelial transitions (EMT/MET) play major roles in both ES 
cell development and CSC transformation (7, 8), it is conceivable 
that EMT is an embryonic link to neoplastic transformation. This 
review hypothesizes that the role of TFs in genetic interactions 
of gametic, zygotic, and ES cells may be related to neoplastic 
transformation in somatic cells.
Gene Translation in Cancer etiology
Gene translation is the final step in phenotypic expression of 
post-transcriptional genes and is therefore important in cancer 
formation and prevention. It is implemented in loops of interact-
ing networks of epigenetic TFs involving alternatively spliced 
mRNA/ncRNA isoforms and effector proteins through binding 
sites at cis-reacting imprinting control regions (ICRs) and UTR 
(untranslated gene regions). Research on potential interactions 
between/among genes involved in gene translation in normal and 
neoplastic cell replications may help elucidate the mechanisms of 
cancer etiology and treatment.
epigenetics Starts in Parental Gametes
Epigenetic TFs control mitotic cell cycles as drivers. They origi-
nate in parental gametes and are transmitted transgenerationally 
to the fertilized ovum. In the zygote, pronuclear TFs interact 
with, and translate, genes of their fusion partners, trigger cleav-
ages of the zygote, cause zygote-to-ES cell switches, and induce 
proliferation/differentiation of diploid gamete-to-zygote-to-
embryonic stem (GZES) cells. It is now well established that 
parental occupational exposure to environmental carcinogens 
(9) causes damage to proliferating embryonic/germline cells 
as mutations and enzymatic mitotic lesions. Toxicants include 
industrial chemicals, such as dioxine and polychlorite biphenyles 
pesticides, and pharmaceutical products, e.g., cytostatic drugs 
that block gene transcription and may cause permanent damage 
in blastocysts. Even pre- and peri-conceptional exposures are 
associated with disease in the offspring through interfering with 
meiotic and/or mitotic cell cycles (10, 11). For example, alterations 
of temporal and spatial patterns of meiotic DNA replication are 
induced through involvement of proteins SMC1β, RAD21L, and 
STAG3 of the TET1-regulated replication machinery by complex 
cohesion links between meiosis and  cancer (12). Lesions affecting 
embryonic CpG methylation patterns modify histone structures 
of endocrine disruptors, generate pre-neoplastic ES cells, and 
contribute to post-natal neoplastic cell growth (13). It is not 
known whether zygotes have the ability to “learn” and adopt bio-
chemically to genotoxic stress. Importantly, toxic environmental 
effects may be inheritable across consecutive generations even 
without direct continuing environmental exposures (14, 15).
Memory
Memory is based on transcriptional decisions of parental genes 
on events of the past that are mitotically transmitted through TFs 
to ES cells. This requires erasure of preceding/ancestral DNA-
CpG transcriptional patterns through excision-glycosylases 
converting DNA-CpG-5mC (5methyl-cytosine) to 5hmC 
(5hydroxy-methyl-cytosine), to 5cC (5carboxyl-cytosine) and, 
finally, to thymine (16, 17). Modulating TFs enzymes are ten 
eleven translocation proteins (TET), autoinflammatory disease 
proteins (AID), methyl-CpG binding domain4 (MBD4), and 
DNA damage-inducible 45 protein (Gadd45). TETs1–3 are 
involved in converting CpG 5mC to 5hmC. AID operates via 
base excision repair pathways. MBD4 is an intermediate recep-
tor; and Gadd45 is a response demethylase in DNA damage 
(18). Following erasure, parental memory is re-introduced to the 
ES cell genome by genomic programing. Incomplete or faulty 
transmission of memory information can result in abnormal gene 
transcription and post-natal diseases, including transgeneration-
ally inheredited carcinogenic predispositions.
Maternal effect Genes
Transcriptional incompatibilities between parental pronuclei are 
silenced by histone-modulations during interactions in the zygote 
ensuring transcription stability in ES cell development. During 
the first two zygotic cleavages, reprograming is under signaling 
dominance of maternal gonad-specific factor (GSF)–maternal 
effect genes (MEGs) (19). The first two pre-ES cell cleavages 
of the zygote are executed by MEG-dominated TFs. MEGs are 
epigenetic genes transcribed and translated during oogenesis, 
and transmitted to the zygote by the maternal gamete. In fact, 
preformed MEGs contribute largely to the earliest biochemical 
steps of zygote development, in particular during passage through 
the oviduct. In the human embryo, both maternal and paternal 
zygote gene activation (ZGA) at the 4–8 cell stage is implemented 
through MEG-dominated alterations of the CpG histone meth-
ylation status by gene-encoded methyltransferase/demethylases 
(DNMT/DM) (20, 21). MEGs operate in zygotic reprograming 
through numerous maternal factors including cis-acting ZAR1, 2 
(zygote arrest)/ZAR-like (ZARL) proteins in translational control 
sequences (TCS) that bind to maternal mRNAs at 3′UTR (22). 
Mutant ZAR1 arrests late 2-cell-stage zygotes through abnormal 
methylation of histones H3K4/H3K9 (histone H3 lysine4/9) and 
downregulate chromatin-modifying genes Dppa (maternal factor 
Stella, peri-plasmic polypeptide haloalkane dehydrogenase) and 
Piwil2 (protein of the ARGONAUTE family) (23). Also involved 
are Akt-PI3K (phospho-inositide-3-kinases) and genes Mil1/
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Blimp1 (transcription repressors of somatic genes Hox and Snail). 
Maternal modulating TFs include cis-reacting RNA-binding 
proteins (RBPs), cytoplasmic polyadenylation elements (CPEs), 
and “deleted-azoospermia-like” (DAZL) family. CPEs mediate 
adaptation of gonadal homeostasis, metabolism, gene transcrip-
tion of cell cycle cyclins, and apoptosis. DAZL is an mRNA 
translational component that controls RBP networks in the initial 
stages of zygote development until the embryonic genome is 
composed at the third post-fusion cleavage (24, 25). In addition to 
zygote reprograming, MEGs affect CTCF-DNA binding sites for 
paternal–maternal gene interactions at ICRs insulator sites (26) and 
licencing processes (21). CTCF is a zinc finger CCCTC repressor 
protein for gene regulation. Other MEG targets include somatic and 
imprinted genes, such as Nlrp1/2 (early zygote, blastomere apop-
tosis), Nlrp5 (Mater), subcortical maternal complexes (SCMC), 
Nlrp14 (nucleotide-binding oligomerization in early embryonic 
development), Hsf1 (heat shock), Npm2 (nucleoplasmin), Cdh1 
(e-cadherin), Pms2 (mismatch repair gene2), Ezh2 (enhancer of 
zeste, essential for ES cell self-renewal), and Smarca 4 (Brg1).
Clearly, MEGs exert fundamental influences on the develop-
ment of the ES cell genome. They transmit genetic/epigenetic 
maternal memory information to the early stages of zygote-to-
ES cell switches (27). They establish specific transgenerational 
transcription links for embryonal genes between parent memory 
and imprinted genes from PGCs (26, 28, 29). MEG mutations and 
functional distortions cause embryonic arrest at different devel-
opmental stages. Mutant genes Npm2, Dppa3, Zar1, and Hsf1 
arrest one-cell zygotes, while mutant Dppa3, Pms2, Dnmt3a, and 
Dnmt1o arrest later stages. MEG failures can cause carcinogenesis 
labeled by exposure-specific biomarkers for transgenerational 
disease and parental environmental exposures (9).
Binding Sites
Binding sites are gene-specific molecular moieties through 
which genetic/epigenetic partners interact with one another (6). 
Binding capacities are inherent properties of TFs for epigenetic 
control of gene transcription/translation. They operate through 
mRNA, ncRNA, and ribosomal proteins in regular as well as in 
pre-neoplastic mitotic cell cycles and are particularly important 
in clinical expression of neoplasms. TFs binding properties are 
not fixed. Rather, they are variable in embryonic, post-natal, 
and evolutionary development (30). Binding patterns vary in 
strength, are thermodynamically sensitive, and adapt to intra-/
extracellular epigenetic stimuli. Novel genes have their own bind-
ing profiles. Binding properties to proteins are important in drug-
design studies for molecular docking in structural identification 
of functional sites. Targeted inhibition of binding sites could 
serve therapeutic and preventive purposes for specific diseases, 
including cancer (31, 32).
Untranslated Gene Regions (UTRs)
UTRs are a distinct, structurized class of non-coding, mostly 
cis-reacting RNA sequences that synergize with gene-specific 
mRNA-binding sites for a wide range of protein effectors (33). 
3′/5′-UTR proteins and small ncRNAs control the flux of transla-
tion relevant information from the transcriptome to proteomes. 
They promote mRNA stability associated with protein-coding 
sequences at terminal endings of mRNA and of DNA-modifying 
histone genes (34), and regulate equilibria of interacting TFs with 
suppressors p53 and cyclin D1 (CCND1) (35, 36). Interaction spe-
cificities of mRNA-alternative polyadenylation (APA)/isoform 
splicing are regulated by five histone H2A genes at UTR sites. 
3′UTR, in particular, exerts multiple functions in carcinogenesis. 
It controls isoform splicing, activates signaling transduction of 
mutated gene cascades, determines mRNA-bindings to proteins, 
affects protein coding, and thus determines the type, direction, 
and translation of neoplastic transformation.
Cis-reacting imprinting Control Regions
Genes interact with enzymatic TFs at ICRs. ICRs are 
transcriptional/translational sites composed of repetitive, 
germline-derived, differentially methylated DNA sequences on 
chromosomes positioned between eu- and heterochromatin. 
They function as insulators in genomic reprograming by delimit-
ing acetylation-mediated barriers against allele-specific interac-
tions of somatic as well as imprinted genes (26). ICRs separate 
active TFs in euchromatin from neighboring heterochromatic, 
silencing regions. Silencing occurs in synergisms with silent-
information regulator (SIR)-mediated disruption of transcrip-
tion activator complexes and RNA polymerase (Pol) II that 
blocks translation through elongation barriers on nucleosomes 
(37). Transcriptional chromatin lesions are partially compen-
sated at ICRs through repression of histone H3K4me3 (lysine4 
trimethylated histone H3) and polycomb complex1-mediated 
mixed lineage leukemia2 gene (MLL2). Distorted insulators are 
pathogenetic in post-natal diseases, including leukemogenesis, 
most likely through leakages between hetero- and euchromatin 
domains of chromatin modulators (38).
Transcription / Translation Factors
Genes transcribed in mitoses become functional and exercise 
their properties through translation to effector proteins.A mul-
tifunctional mRNA-/polymerase A-binding protein (PABP1) 
serves as scaffold for protein–protein interactions. Production 
of effector proteins is mediated/controlled by translational 
TFs-mRNA/ncRNA. Indeed, unless genes are translated, genes 
are silenced and stored in heterochromatin. Thus, gene tran-
scription and translation are interdependent but distinct and 
consecutive processes that can be separated by the specificities 
of their enzymes. Translating TFs include lysyl-tRNA syn-
thetase (lysRS), isoform1 of translation elongation factor eEF 
that adjusts transcriptional yields to translational needs by 
associating with elongating RNA Pol II at 3′UTR, and cell fate 
effector DACHS. The latter mediates cytoplasmic oncogenic 
translation (for example in EMT) by affecting Y box-binding 
snail proteins. Clearly, it is translation that directs phenotypic 
expression of transcribed DNA sequences and therefore decides 
on the phenotypic, clinical expression of carcinogenic genes.
Pre-mRNAs are formed from DNA templates at UTRs. They 
are specified by APA and RNA-recognition motifs (RRMs) for 
splicing into isoforms [see below, Ref. (39)] with characteristic 
RBPs (40). Specificities are gene encoded through exon-binding 
(5). Different isoforms from a single mRNA control specified 
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phases of diploid zygote-to-GZES cell switches (ZGS) in normal 
and carcinogenic mitoses, thus directing gene development into 
distinct directions (29). After transport to the cytoplasm, mature 
RNA isoforms are stored in cytoplasmic granules (41, 42). 
Enhancer export factor Np13 (a serine–arginine-rich shuttling 
protein) and DEAD-box RNA nucleo-cytoplasmic Dbp5 heli-
cases release mRNA isoforms from storage at distinct times for 
DNA translation. Dbp5s are export factors for ATP-dependent 
remodeling. Translation is terminated by endo-ribonuclease 
RNA-E-dependent ncRNAs (40, 43, 44). Importantly, mRNAs 
are indispensible and frequently overexpressed in carcinogenesis 
and EMT-mediated metastatic dissemination (7, 8, 11, 12, 26, 36).
An important group among TFs is non-coding RNAs 
(ncRNA). They enzymatically regulate pre-mRNA splicing and 
edit mRNA-mediated gene transcription/translation (43, 45). 
Editing consists in interactions with poly (A) binding proteins 
PAN2/3, adenosine-to-inosine (A-to-I) converting enzymes, and 
CCR4-NOT de-amylase complexes (46, 47). Two major groups 
of ncRNAs are distinguished at 3′ and 5′ ribosome-binding sites 
(RBS). Group I uses guanosine, and group II employs the 2-OH 
group of internal adenosine. Both affect stability, biogenesis, and 
target recognition of mRNAs and can be pathogenetic in human 
disease. ncRNA regulators include DNA methyltransferases 
(DNMT), histone deacetylases, and polycomb group genes (6). 
They bind to more than one molecular mRNA domain form-
ing enzyme complexes that compete in crosstalks with several 
different mRNAs (48, 49). Abnormally expressed ncRNA often 
are associated with a poor clinical outcome in cancer patients. 
Because ncRNA usually target entire translation pathways, they 
may be more effective therapeutic targets for enzyme inhibitors 
than mRNA genes or proteins.
ncRNAs comprise several functionally defined subgroups, 
including small (20–30 nucleotide)/small interfering RNAs (s/siR-
NAs) (43, 50, 51), long (more than 200 nucleotides) RNAs (lncR-
NAs), piwi transposion/retrovirus interacting RNA (piRNA) (5), 
and others (52). The subgroups have different functions: sRNAs 
edit high-grade myelodysplastic syndromes (MDS) via transfer 
RNAs (tRNAS) and may provide potential links to apoptosis (53). 
lncRNAs modify translating mRNA affecting proliferation, 
invasive motility, and survival of transcribed genes. They are 
frequently involved in carcinogenesis competing with endog-
enous enhancer-like RNAs (ce/eRNA); guide histone lysine 
methyltransferases through H3K27me3 in enhancer of zeste 
homolog (EZH1) pathways with functional overlaps in EMT-
coding pathways; and, importantly, are involved in stem cell 
pluripotency (54). Secondary protein bindings of lncRNAs differ 
in RNA-protein vs. DNA-protein interactions and in modulating 
gene expression programs. For example, lncRNA HOTAIRM1 
(encoded in the human HOXA gene cluster) is a highly specific 
regulator for gene expression in switches from granulocytic 
proliferation to maturation phases in integrin-controlled cell 
cycles. Furthermore, lncRNAs control gene transcription by 
recruitment of silencing complexes to homology-containing 
loci of the genome. Thus, lncRNAs are important in embryonic 
development and in the pathogenesis of neoplastic diseases (55).
An additional group of indispensible TFs, characterized as 
being “adjuvant,” is shown in Figure 1. Adjuvant TFs are encoded 
Adjuvant 
supportive TFs
Preneoplastic 
ES cell 
population
Interactions in the zygote
of precarcinogenic 
genes from gametes
Latency periods,
storage in heterochromatin
(Re-)Activation,
clinical expression
Gene-encoded 
networks
FiGURe 1 | Requirement of “adjuvant” transcription factors (TFs) at all 
stages of carcinogenesis. Until/unless adjuvant networks are complete 
and ready for support of synergetic carcinogeneic (re)activation of cancer 
stem cells (CSCs), mutated genes will not be phenotypically expressed.
predominantly by metabolic genes. They meet the regional 
requirements for survival and development of normal and pre-
neoplastic cells in particular during transformation into fully 
neoplastic cells. Adaptations include supplies in nutrition, oxygen, 
and energy, for motility/angiogenesis, etc. In  pre-neoplastic ES 
cells, adaptive metabolic alterations may be initiated already in the 
zygote before the first ES cell mitosis and continue into embryonic 
and post-natal development. Adjuvant support must be specific, 
quantitatively sufficient, and well synchronized with the appropri-
ate mitotic stages. This applies in particular to phenotypic expres-
sion of clinical cancer, such as acute leukemias, and to EMT/MET 
in metastatic dissemination of solid tumors. Thus, adjuvant TFs 
are involved in the entire course of normal and neoplastic mitoses. 
Unless and until supportive, adjuvant TFs networks are complete 
and ready for synergetic activation of CSCs, mutated genes will 
not be phenotypically expressed. Rather they will be preserved 
in a pre-clinical state stored in heterochromatin from which they 
may be erased or await conversion to overt disease at some later 
time. Adjuvant adjustments may contribute to latency periods 
between infliction of genomic injury and neoplastic transforma-
tion and frequently extend over periods of years. Therapeutic 
blockage of adjuvant supportive networks might cause transcribed 
 carcinogenic genes to remain untranslated.
Alternative Splicing to isoforms
TFs are enzymes that do not catalyze their targets directly. Rather, 
they control protein production indirectly through isoform 
copies that are produced by alternate splicing. In fact, 90% of 
gene-encoded mRNAs and ncRNAs undergo alternative splic-
ing of their exons (the information-bearing parts of the gene) 
(56). APA is an integrated part of the splicing machinery that 
selectively protects poly (A)-tails of pre-mRNA from enzymatic 
digestion. It is bound to chromosomes, mostly within ±20 base 
pairs up- and downstream of splicing sites. Fip1, a gene-encoded 
subunit of the polyadenylation specificity factor CPSFs, is a 
key regulator of proximal polyadenylation at 3′-UTR-mRNA 
endings. It faithfully maintains distances to neighboring DNA 
sequences through insulators and promotes the production of 
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shortened mRNA isoforms for pluripotency/renewal in GZES 
cells and in neoplastic transforming cells. Copies of mRNAs/
ncRNAs are predominantly spliced by histone H3K36 methyla-
tion. Specific cytoplasmic cleavage factors include polyadenyla-
tion binding proteins (CPEBs) and catalyst-stimulating histone 
factors (CPCFs) (57). Specification of isoform targets is achieved 
by Pols II/III-splicing at C-terminal sequences (58, 59). RNA Pol 
II acts as an RNA-dependent RNA Pol. It initiates gene-specific 
protein synthesis and extends/destabilizes ncRNAs (60). Pol III 
regulates neofunctionalization of ancestral genes (61). Frequently, 
pre-mRNA is spliced into more than one isoform. For example, 
Nanog mRNA, a homeodomain TF for ES cell pluripotency and 
self-renewal (see below), is expressed through several isoforms 
arranged at 3′-UTRs in tandem nucleotides of four alternative 
transcription- and five different polyadenylation-start sites. 
Occasionally, pre-mRNA transcripts are translated into isoforms 
with opposing functions. An example is vascular endothelial 
growth factor (VEGF) isoforms that have pro- as well as anti-
angiogenic properties (62).
Alternatively spliced TFs promote the flow of genomic infor-
mation between transcription and translation. mRNA/ncRNA 
isoforms coordinate transgenerational gene activation via zygote-
to-ES cell switches and in GZES cell physiology (28, 63, 64). 
Differently spliced TFs isoforms alter functional diversity and 
stability in distinct ways that extend TFs properties. Alterations 
in close proximity to exon/intron boundaries may weaken recog-
nition sites of natural splice acceptors or donors and lead to exon 
skipping isoforms at cryptic splice sites. Importantly, TFs isoform 
splicing produces gene duplications with epigenetic properties 
deviating from the original. Leeway copies greatly enlarge the 
functional scope of TFs. They can induce gene neosynthesis (dis-
cussed below) and neofunctionalization of pre-existing, silenced 
(ancestral) DNA sequences endowing them with new CpG 
methylation patterns. Neofunctionalization employs nucleolin 
and Dbp2. Nucleolin acts with RNA regulating motif boxes RRM/
RGG for transcriptional repeats, while Dbp2s (RNA-dependent 
helicases) are co-transcriptional modulators for clearance of 
genomic loci from preceding translations. Dbps control the 
quality of mRNA structures and ribonucleoprotein complexes, 
allow the formation of new chromatin and mRNPs (ribonucleo-
protein) assemblies (65), repress aberrant DNA transcription, 
and promote transcription fidelity. Loss of Dbp2 leads to failure 
of chromatin structuration and distortion of gene expression. 
Neofunctionalization may occur already during embryonic devel-
opment (66), e.g., by elimination of dinucleotides GT or AG at the 
5′ and 3′ ends of introns (13, 41, 67). Isoforms may have abnormal 
exon lengths and a leaky structuration (38, 56). Indeed, distorted 
C-terminal sequences are caused in promyelocytic leukemias by 
abnormally spliced isoforms that silence tumor-suppressor genes 
p53/p63/73 (68, 69). Other variants cause genomic instability and 
chromsome aneuploidy, initiate abnormal protein synthesis and 
may thus act as carcinogenic factors (70).
isoform Splicing in Clinical Carcinogenesis
Splicing of TFs to isoforms plays a central role in clinical onco-
genesis because it can induce gene neogenesis and neofunction-
alization of silenced ancestral genes. The former is discussed in 
the section below. Alternatively spliced carcinogenic isoforms 
specifically direct the translation of mutated genes, but the 
mechanisms of selection for splicing to carcinogenic isoforms 
are still enigmatic. Numerous clinical carcinogenic pathways, 
such as MEK, RAS, and ERK/RAF, employ carcinogenic isoforms 
of high-order chromatin structures that promote neoplastic 
transformation. Also involved in deregulated translation by 
splicing are mRNA kinases such as RUNX1, CBFβ, MLL, 
C/EBPα, SPI1, GATA, and TAL1 that may cause misplacement 
of transcription factor binding-/start sites (TFBS/TSS) (71, 72). 
For example, isoform elF4H1 (spliced from translation-initiation 
elF-mRNAs) activates oncogenic signaling for cell proliferation 
(73). Other isoforms activate dormant mRNAs by opening 
their elongated carcinogenic poly (A) tails. Pre-mRNA variant 
isoform C5-V6-C6 of alternatively spliced exons of CD44 (67) 
(a cell membrane glycoprotein mediating cellular responses to 
the microenvironment) confers metastatic potentials to CSCs in 
EMT (74). This is interesting because EMT–TF complexes are 
involved in the development of both normal and carcinogenic ES 
cells. It suggests that patients with identical cytohistopathology 
may have different isoform signatures that require individually 
adapted anti-neoplastic therapy.
Modes of translation differ in different types of neoplasms. 
Some switch to translation by neoplasm tic splicing only during 
proliferation; others, mostly of poor clinical prognosis, periodi-
cally turn dysregulated gene-specific ncRNA/mRNA interactions 
on and off. Still others monitor translation of gene transcriptomes 
by spontaneous expression of their own disease-associated 
isoforms without epigenetic triggers (75, 76). For example, car-
cinogenic isoforms like POLR2K are preferentially upregulated 
in leukemic and other neoplastic tissues (38, 58). In pulmonary 
adenocarcinomas, multimeric cis-regulating isoform variants 
of nicotin receptors modulate missense single-nucleotide poly-
morphism (CHRNA5) at coding loci. In endometrial adenocar-
cinogenesis, expression of pathogenetic fibroblast growth factor 
receptors (FGFRs) is altered by isoforms. In bladder carcinomas 
and chronic lymphocytic leukemias, neoplastic cell proliferation 
is promoted by newly acquired replication-dependent mRNA 
isoform H2A1C and H2A1B/E. (In contrast to canonical H2A, 
these variants result from mutations in five histone H2A encoding 
genes at end positions of UTRs 3′ and 5′). In EMT of breast can-
cer, spliced isoforms including hMENA (a regulator of the actin 
cytoskeleton expressed in pre-mRNA lacking exon VI) appear 
in malignant invasive progression. Central coordinators ESRP1, 
2, mediating carcinogenic splicing and differentially regulated 
isoforms such as TPAP2A, may affect tamoxifen therapy.
Clearly, carcinogenic isoform variants of TFs are of key 
importance in neoplastic translation and phenotypic expression. 
This complies with the concept of carcinomas being epigenetic 
diseases (11). It is a matter of speculation whether the final deci-
sion for clinical expression of carcinogenic genes also depends 
on the ability of the genome to “learn” adopting their splicing 
behavior in epigenetic environmetal networks to altered gene 
replication patterns (15). As tumor markers, isoforms prove 
sensitive to specific biochemical therapeutic inhibitors (77, 78). 
For example, in treatment of colorectal cancers, variant isoforms 
should be selected.
Isoforms
gene neosynthesis
Mutated Normal 
ncRNA
(isoforms)
SynthesisCarcinogenic Normal proteins
mRNA
Translation
Translation/  
storage
FiGURe 2 | Neoplastic translation determined by ncRNA-modified 
mRNA isoforms.
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Novel Genes
De novo synthesis of genes has a major impact on evolutionary 
traits. Indeed, genomes adopt to new epigenetic situations, 
such as transgenerational information, exposure to environ-
mental carcinogenic contaminants, and other forms of biotic 
stress that are known to be mutagenic in ES cells (9, 11, 13, 
14, 79). Functional alterations are introduced either by gene/
protein neofunctionalization (discussed above) or by TFs neo-
synthesis for selected mutated genes. Translation of the latter 
is implemented by spliced isoforms that introduce new CpG 
methylation patterns at sites of DNA “hotspots” (3). Details of 
selecting TFs from reservoirs of protogene substrates for car-
cinogenic gene splicing and propagation in mitotic replication 
forks remain engimatic (5). Materials for DNA neosynthesis 
are raw, open to modulations by chromatin histones. MEG-
derived ubiquitin-mediated proteolysins1 (ZAPAC-Ump1) 
(80) predominantly control the synthesis of novel genes during 
gamete-to-zygote transitions (MZT) (21, 81). Interestingly, this 
includes encoding of DNA templates for zygotic TFs-mRNA/
ncRNA and proteins that mediate transgenerational transmis-
sion of parental memory (82). Also involved are numerous 
supportive factors, including CCR4-NOTs and CTCF. The 
latter is a multifunctional transcription zinc finger repressor 
with insulator qualities. Its binding patterns shape DNA–pro-
tein interactions for evolving new gene expression. A recent 
database of CTCF-binding sites is available (83). CCR4-NOT 
complexes are recruited by sequence-specific mRNA-binding 
proteins including Nanog. They modulate gene translation by 
deadenylase-catalyzing enzymes, and facilitate decay processes 
of epigenetic, gene-encoded mRNA-independent allelic poly (A) 
tails and of co-translational proteasomal proteins. Complexes 
appear to bind to 3′-UTR-mRNA elements via ncRNA (84). 
Interestingly, CCR4, through its subunit NOT5, connects 
transcription with translation. Novel TFs identify overlapping 
domains and modify transcription/translation patterns of 
parental pre-PGCs and GZES cells to mature to embryonic 
germ cells (PEGCs) (85). Thus, interactions of parental genes 
in the zygote reprogram PEGCs as a key source for stem cell 
memory persisting throughout life (28, 86). Novel genes can 
also affect splicing of additional RNA isoforms,  protein–DNA 
and protein–protein interactions, including tandem repeats of 
neoplastic mutations (13, 87).
If functionally superior, isoform copies are introduced as new 
TF-coding genes into the genome for persistent expression in clini-
cal translation and establish carcinogenic genes (3). Thus, novel 
genes obtained by neofunctionalization and gene neosynthesis 
individualize the genomic uniqueness of ES cells. Novel genes 
generate new epigenetic networks of TFs with histone-modified, 
binding site-specificities that may overlap with other biosynthetic 
pathways (6, 88). Re-writing of entire genomic programs enables 
TFs of ES, post-natal, and, to some extent, neoplastic stem cells 
to respond to environmental stimuli by selecting, targeting, 
steering of DCSGs (duplication copies of selected genes), and 
altering epigenetic gene-silencing. Re-writing proceeds synchro-
nously in GATA1-regulated complexes driven by context-specific 
nucleosomes that may determine the clinical outcome of cancer 
patients (89, 90).
Pre-Neoplastic Gene Translation
Carcinogenesis is a slowly developing, multifactorial, highly 
synchronized process that requires preparatory gene-encoded 
epigenetic steps. Every cancer has its own neoplastic history 
that may originate already during embryonic development (13, 
91, 92). Pre-neoplastic lesions are shaped at 3′/5′-UTRs from 
parental isoforms carrying oncogenic memory into abnormal 
translating DNA templates. It can, therefore, be assumed that 
cells with pre-neoplastic properties are present in normal ES cell 
populations. Because gene-encoded isoforms of mRNA/ncRNA 
TFs catalyze translation of post-transcriptional genes, variants 
of abnormally spliced tumor-specific TF isoform will deter-
mine the expression of carcinogenic/mutated genes. Indeed, 
through gene neogenesis/neofunctionalization, TFs variants 
may generate pre-neoplastic subpopulations among ES cells. In 
addition, carcinogenic isoforms of ppTFs could establish links 
for interactions with pre-cancerous genomes during zygote-
to-GZES cell switches and contribute to decision-making in 
transgenerational translation of mutated genes (5, 35, 56, 92), 
presented in Figure 2.
Examples of clinically apparent pre-neoplastic lesions in con-
genital/childhood acute myeloid/promyeloid leukemias (35, 93) 
include new AML1-ETO/ERG binding sites, FLI1 demarcating 
targets of aberrant epigenetic regulation and chromatin acces-
sibility, retinoic acid receptors, and histone acetylation (94–96). 
It is of great interest to collect more information on the selection 
of splicing duplication copies for isoforms that induce neoplastic 
transformation. Research needs to be done with regard to when, 
and at what occasions in an embryo/patient’s life time, specific 
carcinogenic lesions are introduced into the genome; how the 
multitude of crucial metabolic alterations are gene-encoded 
as adjuvant TFs; how they are synchronized during storage in 
pre-carcinogenic cells; and whether anti-neoplastic defense 
mechanisms exist in zygote/GZES cell switches.
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epigenetics of the Zygote
Forming the zygote by fusion of the two haploid parental pronuclei 
is a critical event in embryonic development because the diploid 
pluripotent ES cell genome that controls the entire biological life 
of the offspring is initiated in the zygote (26). Until fertilization, 
the two gametes had separate, independent epigenomes each 
carrying its own transcriptional memory (97). Zygotic fusion 
changes the situation drastically: now, the one-cell zygote acco-
modates bi-nucleate transcriptional information from the still 
separate haploid genomes of both parental pronculei. Zygote 
formation is initiated through activation of adhesion molecules 
that bind cis-positioned proteins at oocytic nuclear matrix sites 
(MARS) to surface membranes of the decondensed spermatocyte 
(98). Maternal fusogens (of the CD9 tetraspanin TF family) 
allow the spermatocyte to enter the oocyte through IgSF receptor 
IZUMO1. Within 3  h of fusion, the spermatocyte terminates 
maternal meiotic phase II permitting gene programing for the 
somatic diploid zygote/ES cell genome (99).
Zygote nuclear programing is initiated through pronuclear 
ZGA by catalyzing TFs that also act as drivers for GZES cell switches 
(81). It is implemented during the first two cleavages, prior to the 
first diploid zygotic mitosis at the third, four- to eight-cell division 
(27, 82), after DNA-CpGs methylation patterns have been altered 
by chromatin histones, namely proliferation-promoting histones 
(H3K4/H3K9/H3K18/H3K27), repressive H4K12 acetylation, and 
H3S10 phosphorylation (21, 24). TFs employ methyltransferases 
DNMT3a/b/1 and polycomb EZH2 proteins for DNA program-
ing (100). DNMT3A is regulated by DNMT3L and DNMT3b in 
regulatory feedback loops of mRNA isoforms. Methyl groups from 
parental DNA are copied by DNMT1 onto de novo synthesized 
daughter strands. Mutant DNMT1s cause loss of DNA methyla-
tion, distortion of gene expression, and/or mitotic arrest. Histone 
deacetylases control mitotic cycle progression. Their inhibitors, 
histone deacetylase inhibitors (HDACi), have been used in anti-
neoplastic therapy (77, 101, 102). Phosphorylation changes affini-
ties of binder proteins to reader/writer modifications that affect 
crosstalks between histones exerting spatio-temporal controls of 
chromatin-associated events (103). ppTFs, such as somatic Oct4, 
Nanog and Sox2, assume special positions in ES cell renewal and 
in transformation of CSCs. This is separately discussed below in 
Sections “Zygote-to-GZES cell switches” and “Origin of carcino-
genic ppTFs.” Mistakes in interactions of post-fusion pronuclear 
and zygotic genes lead to severe GZES cell damage, abortions, 
malformations, and post-natal diseases (46, 104), including 
mismatches in competitive gene-silencing during intra-S-phase 
surveillance in leukemogenesis (38).
Imprinted genes also are involved in the generation of diploid 
GZES cell genomes. They are either reconfirmed by re-imprinting 
in their former parental DNA-CpG methylation patterns, or are 
replaced by newly imprinted somatic genes. Imprinting is imple-
mented by selective TFs-mediated CpG methylation. Catalyzing 
enzymes are TET1, 2 and KDM1B demethylases, and isoforms 
of DNMT1s and DNMT1o (derived from DNMT1) (105). The 
paternal genome is re-/imprinted around puberty, independ-
ent of fertilization (99). It induces regulatory epigenetic marks 
for histone packaging and chromatin stabilization in late fetal 
development (21) in particular in genes Igf1, 2/Igf2Rs, Peg3, 
Zim1, H19, and Zac1 (100, 106). In the maternal pronucleus, re-/
imprinting is initiated upon release from meiotic silencing within 
the first post-fertilization hours preceding ZGA (97). Imprinted 
genes appear to be particularly vulnerable to distortions of dif-
ferential marks (49, 99, 106), but are protected by maternal Stella 
DPPA3s (107) from additional alterations during somatic pro-
graming. Abnormally imprinted genes may cause developmental/
clinical disorders by promoting survival of pre-cancerous cells 
among normal ES cell populations (13, 28, 108, 109).
Zygote-to-GZeS Cell Switches
Transfer experiments have shown that nuclei of end- differentiated 
cells, such as mature fibroblasts, can be reprogramed back to full 
embryonic pluripotency of GZES cells by cytoplasmic TFs from 
enucleated oocytes (110). Thus, embryonic TFs can establish 
transcriptional links between GZES and other types of stem cells, 
including pre-/neoplastic cells (13, 58, 111). In fact, gametes 
transmit to the zygote genomic inheritable information on paren-
tal neoplastic memory for processing during generation of GZES 
cell genomes, along with normal information (83, 112). Signaling 
programs sharing information on transformation of self-main-
tenance and migration are conveyed to both ES cells and CSC, 
for example by reversible EMTs. They are driven by TFs SNAIL/
TWIST and ZEB (7, 8) and completed by de novo synthesis of 
embryonic TF isoforms (12, 92). Linking embryonic to neoplastic 
transcription is mediated by common, or closely related, ppTFs 
such as Nanog, Oct4, and Sox2. ppTFs that operate in regula-
tory signaling pathways of the cell cycle of both GZES and CSC 
are hallmarks of unlimited proliferation and self-renewal. They 
synergize with one another, with other types of isoforms, and 
with lncRNA as scaffolds for chromatin-modifying complexes 
(4, 113, 114). ppTFs are encoded by genes WNT/β-catenin (115, 
116), JAK/STAT (117, 118), NOTCH (119), MAPK/ERK (120), 
and PI3K/AKT (121). JAK (Janus activating tyrosine kinase) 
triggers the Wnt/β-catenin pathway (encoded by gene Ctnnb1) 
as tumorigenic gatekeeper in GZES cells for myeloproliferative 
diseases (116, 118, 122). The Notch pathway controls intercellular 
communication. MAPK/ERK are mitogen-activated/extracellular 
signaling pathways. PI3K is a phosphoinositide-3-protein kinase.
Oct4 is a master gene for pluripotency and self-renewal of 
undifferentiated GZES cells (123). It is expressed in oocytes, PGCs, 
and the embryonic inner cell mass (ICM) of pre-implantation 
blastocysts (124). Oct4 operates through ubiquitin E3 ligase Itch 
that is involved in self-renewal, pluripotency induction, somatic 
cell reprograming, and protein stability of transcribing ES cells 
(125). In cultures of heterologous Oct4± ES cells, Oct4 strongly 
binds to key regulatory chromatin histones. This increases Wnt 
signaling for enhanced cell sensitivity to LIF (leukemia inhibitory 
factor), reinforces network pluripotency, and promotes resist-
ance to differentiation. Switches to homologous TF expression 
(Oct4+/+) induce GZES cell differentiation (4). Oct4 also is a key 
determinant of gene expression by CSCs. Although it acts as a 
general neoplastic TF in EMT-mediated stemness signatures, 
it may not be a specific neoplastic driver (123, 126). Oct4 in 
p53-miRNA-34a/p63 miRNA-34a loops (127, 128) affects leu-
kemogenic signaling pathways through balances between p63 
ES cell genes
Silencing
precancerogenic
normal
Silencing
Reactivation by
Reactivation by
cancerogenic ppTFs
normal/ 
cancerogenic ppTFs
Cancer cells
FiGURe 3 | Links between normal embryonic and pre-neoplastic transcription factors (TFs).
+A
B
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F
Mutagens 
FiGURe 4 | Transgenerational transmission of carcinogenic gene 
lesions. (A) Parental gametes; one being hit, e.g., by an environmental 
insult (mutagen). (B) Fertilization, fusion of gametes, and formation of the 
zygote. (C) Interactions during the first two zygote cleavages of post-
fusion parental genes, including genes carrying pre-neoplastic DNA 
damage, are modulated by chromatin histones. (D) Genes with pre-
neoplastic DNA lesions participate in zygote-to-ES cell switches (e) 
Pre-neoplastic genes are included in the internal cell mass. (F) Overt 
carcinogenesis.
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stimulation and p53 downregulation (129). Other pathways such 
as Lin28/Oct4 in ovarian cancer (130), carry Oct4 as a promotor 
bound to cyclin D1 (CCND1) protein. A data base is available 
on integrated retrival of Oct4 related in human and mouse ES, 
embryonic cancer cells (ECC), and CSCs (131).
 Pluripotent TFs Nanog programs and maintains pluripotency 
of naïve ES cells at the target locus Esrrb synergizing with Oct4–
Sox2 binding motifs (132). Nanog levels in the ICM are stimulated 
by adenylate cyclase and are downregulated in JAK/STAT path-
ways (133). In complexes with 5mC hydroxylases TET1/2, Nanog 
determines cell fate and pluripotency of ES cells and CSCs (131, 
134) and implements tissue specificities of genes Brca1 (modula-
tor of cellular stress/repair), Trp53 (tumor repressor), and Rb1 
(retinoblastoma suppressor) (135, 136). Overexpressed Nanog 
may act as driving factor in cell proliferation and self-renewal of 
human and murine neoplasms by controlling molecular stemness 
in Wnt/β and Tcf3/Tcf1β-catenin signaling pathways (137).
Sox2 protein is involved in pre-implantation development. It 
is expressed in 16-cell bovine embryos and is restricted to the 
ICM. Sox2 operates in negative GZES cell feedback loops of Akt 
signaling and binds to Fox01, a nuclear TF in metabolic and 
energy homeostasis (138). Increases of Akt serine/threonine 
kinase cause decreases in endogenous Sox2 in association with 
losses of Fox01 (121, 127, 139). In metastasizing neoplasms, Sox2 
stimulates signaling pathways Wntβ-catenin EMT (140).
Origin of Carcinogenic ppTFs
Although, clearly, ppTFs are indispensible drivers for pluripotent 
proliferation/self-renewal in both ES and neoplastic cell transfor-
mation, the origin of carcinogenic ppTFs in CSCs is still elusive. 
In Figure 3, questions of links between normal embryonic and 
carcinogenic ppTFs are raised: are they biochemically identical 
or can they be distinguished from one another? Do TF isoforms 
acquire carcinogenic propeties during splicing and, if so, how? 
Are carcinogenic ppTFs derived from normal ppTFs or are they 
generated sui generis? What triggers functional alterations? Are 
pre-neoplastic ES cells activated by both, normal and neoplastic 
ppTFs? Or are the latter generated through TF gene mutations 
from primordial germ cells, through reactivation of silenced 
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embryonal TFs, or through neosynthesis via mRNA/ncRNA 
spliced isoforms? What functions of ppTFs are reversible in 
EMT/MET? A recent study suggests on the basis of molecular 
differences in functionally separable ppTFs that neoplastic 
ppTFs are not reactivated from silenced ES cells, but rather are 
distinct regulators in newly composed epigenetic networks (141). 
So, it remains an unsettled question how genomic interactions 
of ppTFs link embryonic/normal with neoplastic development 
(142–147).
epigenetic Anti-Neoplastic Therapy
Therapeutic enzymatic reprograming of the genome aims to alter 
the developmental fate of CSCs. It is hoped to abolish or mitigate 
carcinogenic cell properties in favor of normal gene functioning 
by reversing transcriptional signatures. Potential therapeutic 
targets are transcription-driving molecules in transport, bind-
ing of nuclear/cytoplasmic receptors, and drug-metabolization. 
Enzyme inhibitors focus on neoplasm-specific TFs of gene 
imprinting, mono-allelic transcription, post-transcriptional gene 
translations, and ZGS (78).
Promising attempts of interfering with enzymatic reac-
tions have so far mostly been limited to in  vitro cell lines, but 
clinical studies are in progress. Drugs include decitabine 
(5-ara-2′-deoxycitidine), HDACi, H3 histone acetylator of 
tumor-suppressor gene PRDX2, and polo-like kinase SNK/PLK2 
(a transcriptional target for wild-type p53). Other approaches 
have re-enforced tumor suppressor genes by inhibition of lysine-
specific LSD1 demethylase for H3K4me1, 2 in acute myelogenous 
leukemia and small cell lung cancer by activation of all-retinoic-
acid differentiation pathways, or have altered DNMT-mediated 
DNA-CpG methylation patterns (1, 94). Indeed, carcinomatous 
cell growth should be classified according to its sensitivity to 
drug-inhibiting key enzymes.
Summary
Genetics and epigenetics constitute a functional entity in embry-
onic and post-natal cell proliferation. This review focuses on 
potential gene interactions in cell cycles of gametes, zygotes, and 
ES cells that may be related to neoplastic transformation. Figure 4 
presents steps of transgenerational transmission of carcinogenic 
information: Carcinogenic epigenetics may be initiated during 
pre/conception and gestation through environmental exposure to 
mutagens (Figure 4A). Exposures may cause abnormal exchanges 
between recombining alleles during parental meiosis or during 
pronuclear interactions in the zygote, and generate abnormally 
spliced TFs (mRNA/ncRNA) isoforms that are transmitted to 
GZES cells. Isoforms may induce gene neosynthesis and neo-
functionalization of silenced pre-existing (ancestral) TFs genes. 
Carcinogenic pre-/information can be caused by TFs duplica-
tion copies that deviate biochemically/functionally from their 
originals. Abnormal information is transmitted to the zygote, 
participates in nuclear programing, and is incorporated in the 
zygotic genome (Figure 4B). Early transgenerational transmis-
sion by ZGA is dominated by maternal effect genes MEGs in 
both pronuclei. Pre-/neoplastic DNA damage is modulated by 
chromatin histone H3 methylation/acetylation and interacts 
with its zygotic fusion partner (Figure  4C), predominantly 
during the first two zygote cleavages. This establishes parental 
oncogenic memory in the zygote. Pre-neoplastic DNA lesions 
participate in ZGS mediated by abnormally spliced carcinogenic 
TFs isoforms (Figure 4D), and are included in the ICM of the 
embryo (Figure 4E). Clearly, further research needs to be done 
on carcinogenic splicing of TFs isoforms.
In clinically overt carcinogenesis (Figure 4F), carcinogenic TF 
isoforms are organized in epigenetic networks alongside normal 
TFs, operating through specific binding sites. Carcinogenic 
transgenerational inheritance appears to be connected to normal 
GZES cell development by signaling links provided by ppTFs, 
such as Oct4, Nanog, and Sox2. In fact, ppTFs convey prolifera-
tive, self-maintaining, invasive/migratory genomic programs to 
both normal and pre-neoplastic daughter cells. Whether ppTFs 
are biochemically identical in both instances is unknown. 
Pre-carcinogenic transcriptional information is storaged in 
heterochromatin waiting for post-natal triggering by additional 
stimuli in synergy with full support from adjuvant metabolic TFs. 
Possibly, equilibria between ppTFs of normal and carcinogenic 
translation could be pushed therapeutically in favor of normal 
translation. Thus, TFs are cell/disease-specific messengers that 
may trigger the expression of clinically overt neoplasms by decid-
ing on post-natal carcinogenic gene translation. Accordingly, 
carcinomas have recently been defined as “epigenetic diseases.”
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Appendix
Abbreviations
5hmc, 5hydroxy-methyl-cytosine; 5mc, 5methyl-cytosine; 
A-to-I, adenosine-to-inosine; AID, autoinflammatory disease 
proteins; ALL, acute lymphoblastic leukemia; AML, acute 
myelogenous leukemia; AML-ETO, t(8;21)AML; APA, alterna-
tive polyadenylation; Blimp: transcription repressor of somatic 
Hox and Snail genes; BRCA1: modulator of cellular stress and 
DNA repair; with a protective role in autophagy in tumorigen-
esis/prognosis; C2-WW-HECT: Smad ubiquitylation (Smurf1) 
domain E3; mediated by a protein–protein WW linker; CBFβ: 
transcription cofactor to the ubiquitin ligase complex; CCND1: 
cyclin D1 has an essential role in cancer progression; CCR4-
NOT: a multi-subunit de-amylase complex that regulates gene 
expression; CD44, cell membrane glycoprotein, alternatively 
spliced exon; Cdh1, e-cadherin; C/EBP, CCAAT enhancer 
binding protein; CHRNA5, missense coding single-nucleotide 
polymorphism (SNP); CLL, chronic lymphatic leukemia; CPE, 
cytoplasmic polyadenylation element; CPEB, binding proteins; 
CpG, cytosine phosphate guanine; CPCF, catalyzation specificity 
factor; CPSF, polyadenylation specificity factor; CSC, cancer stem 
cell; CTCF, transcription repressor CCCTC zinc finger protein for 
gene regulation; Ctmb, cellulose tris (4-methylbenzoate), a cubic 
transport model base; DACHS, a cell fate factor (Dachshund) that 
mediates oncogenic transcription and translation by suppressing 
EMT; DAZL, deleted-azoospermia-like; Dbp2, RNA-dependent 
helicase; Dbp5, mRNA export factor in ATP dependent remod-
eling of RNA/protein complexes; DCSG, duplication copies of 
selected genes; DEAD, Dbp5 nucleo-cytoplasmic proteins; DM, 
DNA demethylases; DNMT, DNA methyltransferase; Dppa, 
periplasmic polypeptide haloalkane dehydrogenase (maternal 
factor Stella); e1F4H1, spliced translation-initiation e1mRNA; 
ECCs, embryonic cancer cells; eeRNA, endogenous enhancer 
RNA; eEF1A1 isoform, translation elongation factor; EMT/
MET, epithelial-mesenchymal/mesenchymal-epithelial transi-
tion; ERG, FL1, closely related members of the; ETS family of 
transcription factors; ES, embryonic stem (cells); ESRP, central 
coordinator; Ezh, enhancer of zeste homologe; FGFR, fibroblast 
growth factor receptor; Fip1, mRNA3 processing factor essential 
for ES cell self-renewal and somatic cell reprograming; Fip1/1, 
gene encoding Fip1; FL1, transcription factor; Foxo1, nuclear 
transcription factor, especially in metabolism and energy 
homeostasis; Gadd45, DNA damage-inducible45 protein; GATA, 
transcriptional regulator proteins; GSF–MEG, gonad-specific 
factor–maternal effect genes; GW182, key regulator of neuropep-
tide PDF signaling; GZES, gamete-to-zygote-embryonic stem 
(cells); H1(0), linker histones; H2A1B/E, H2A1C, replication 
dependent isoforms; H3K, histone 3 kinase; HDACi, inhibitors 
of histone deacetylase control; hMENA, human regulator of the 
actin cytoskeleton; HOTAIRM1, encoded in the human HOXA 
gene cluster; HOXA, HOXA genes are regulators of normal and 
malignant hematopoiesis; Hsf, heat shock; ICM, internal cell mass 
of the early embryo; ICR, cis-reacting imprinting control regions; 
Igf, insulin-like growth factor; IgfR, insulin-like growth factor 
receptor; IgSF, immunoglobulin superfamily that inhibits adhe-
sion to endothelial inflammatory ligands; Itch, E3 ligase; Izumoi, 
oocyte IgSF receptors for sperm entry; JAK, Janus activating 
tyrosine kinase; JAK/STAT, stem cell regulating signaling path-
way. Misregulations can be involved in cancer; KDM1B, a H3K4 
demethylase for maternal genomic imprints; LIF, leukemia inhibi-
tory factor; lncRNA, long ncRNA; LysRS, lysyl-tRNA synthetase 
that inactivates translational functions in favor of transcription 
through factor MITF; MAPK/ERK, mitogen-activated protein 
kinases/extracellular-signal-regulated kinases; Key regulators of 
cancer hallmarks; MARS, matrix attachment site; MBD4, methyl-
CpG binding domain 4; MDS, myelodysplastic syndrome; MEGs, 
maternal effect genes; MEK, includes seven kinases that participate 
in the RAS/RAF/MEK/ERK signal transduction pathway; MIL1, 
microsporeless1, a high-affinity blocker of mouse IL1alpha/beta; 
MLL, mixed lineage leukemia gene; mRNP, ribonucleoprotein; 
Myc, oncoprotein, TF that regulates the expression of many genes 
involved in cell growth, proliferation, and metabolic pathways; 
MZT, maternal-to-zygote transition; Nanog, homeodomain ppTF 
of ES cells; ncRNA, non-coding RNA; Nlrp, early zygote blastomere 
apoptosis protei; Notch, intercellular communication pathway 
with key roles in congenital/neoplastic diseases; Npm, nucleo-
plasmic; Oct4, a pp TF; PABP1, poly A-binding, ubiquitous, mul-
tifunctional MRNA1 protein; PAN2/3, poly(A) binding proteins 
2,3; Peg3, imprinted regulating gene domain e.g., for fetal growth 
and maternal caring behavior; PEGS, primordial embryonic germ 
cells; PGCs, primordial germline cells; PI3K/AKT, phospho-
inositide-3-protein kinase; Piwi, protein of the ARGONAUTE 
family; piRNA, piwi, retrovirus interacting transposon; PML, 
promyelocytic leukemia; Pms2, mismatch repair gene2 mutation; 
Pol, polymerase; POLR2K, isoform, preferentially upregulated in 
cancer cells; POUF, homeobox gene Pit-1 encoded TF; ppTFs, 
pluripotent TFs; Rb1, retinoblastoma suppressor gene; RBP, RNA 
binding protein; RBS, ribosome binding site; RGG, motif boxes 
rich in argenine and glycine; RRM, RNA regulating motif; RUNX, 
mRNA kinase, hematopoietic TFs; SCLC, small cell lung cancer; 
SCMC, subcortical maternal complexes; SIR, silent information 
regulator; siRNA, small interfering ncRNA; sRNA, small, ncRNA; 
Sca1, CD133, CD34, ALDH1, CSC markers; Smarca4, Brahma 
related gene1 (Brg1); Snail, transcriptional factor for cell inva-
sion, that downregulates E-cadherin and upregulates MMP; SNK/
PLK, serum-inducible, polio-like kinase, a tumor suppressor in 
B-cell malignancies; Sox2, a ppTF, embryonic stem cell marker; 
SPI1, key gene for hematopoietic regulation and leukemia sup-
pression; TAL1, hematopoietic regulator; Tcf, T-cell factor; TCS, 
translational control sequence; TFBS, TF binding site; TPAP2A, 
differentially regulated isoform; TSS, TF start site; TET, ten eleven 
translocation protein; TF, transcription factor; TRNA, transfer 
RNA; Trp53, tumor repressor protein; TWIST, basic helix-loop-
helix transcription factor that promotes cancer metastases; UTR, 
untranslated region; VEGF, vascular endothelial growth factor; 
Wntβ-catenin, signaling pathway in embryonic and adult human 
stem cells. Deregulations can be involved in developmental and 
genetic diseases including cancer; Zac1, zinc finger protein1 that 
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regulates apoptosis; ZAPAC-Ump, maternally derived ubiquitin-
mediated proteolysin; ZAR, zygote arrest; ZARL, ZAR-like; 
ZBE, Zinc finger binding element and transcriptional activator 
of Znf131 involving; sequence-specific Kaiso binding sites; 
Kaiso is a negative regulator of the Wnt/β-catenin TCF signaling 
pathway; ZEB, family of transcription factors in embryonic devel-
opment that also induce EMT in cancer invasiveness and CSC 
stemness; ZGA, zygote gene activation; ZGS, zygote-to-GZES 
cell switches; Zim1, maternally expressed trans factor controled 
by paternal Peg3.
